Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab

202260 citationsJournal Articlebronze Open Access

Authors

Todd L. Rosenblat · Columbia University Irving Medical Center

Michael R. McDevitt · Memorial Sloan Kettering Cancer Center

Jorge A. Carrasquillo · Memorial Sloan Kettering Cancer Center

Neeta Pandit-Taskar · Memorial Sloan Kettering Cancer Center

Mark G. Frattini · Intellicell Biosciences (United States)

Peter G. Maslak · Memorial Sloan Kettering Cancer Center

Jae H. Park · Memorial Sloan Kettering Cancer Center

Abstract

Therapy for AML with the targeted α-particle generator 225Ac-lintuzumab was feasible with an acceptable safety profile. Elimination of circulating blasts or reductions in marrow blasts were observed across all dose levels.

Topics & Keywords

Radiopharmaceutical Chemistry and Applications Peptidase Inhibition and Analysis Monoclonal and Polyclonal Antibodies Research

Publication Details

Published in: Clinical Cancer Research

Volume 28, Issue 10, pp. 2030-2037

DOI: 10.1158/1078-0432.ccr-21-3712

Field-Weighted Citation Impact: 7.92

Command Palette

Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab

Authors

Abstract

Topics & Keywords

Publication Details